C4X Discovery Company

C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular structures with high accuracy, C4X Discovery is focused on optimising the design and development of medicines and partnering with the pharmaceutical sector to generate better, safer products. C4X Discovery is able to determine the bioactive 3D structures of a variety of biologically important molecules, including drugs, naturally occurring ligands and enzyme co-factors, and does this independently of traditional methods such as computational modelling and X-ray crystallography. C4X Discovery is applying its unique technology to improve the efficiency of the drug discovery process, both in partnership with the pharmaceutical industry and across its own pipeline of high-value therapeutic targets.
Technology: Biotechnology, Life Science, Pharmaceutical
Industry: Preclinical Development
Headquarters: Manchester, Manchester, United Kingdom
Founded Date: 2007-01-01
Employees Number: 11-50
Funding Status: IPO
Acquisitions Number: 1
Investors Number: 2
Total Funding: 6710238
Estimated Revenue: $1M to $10M
Last Funding Date: 2016-09-06
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership